New drug for HER2-low advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new HER2-targeted antibody drug (TQB2102) against standard chemotherapy in people with HER2-low breast cancer that has spread or come back. It aims to see if the new drug works better or is safer than usual chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced breast cancer that is HER2-low, meaning it has a little bit of HER2 protein but not high.
- You should be between 18 and 75 years old and have a good performance status (able to get around and care for yourself).
- You need to have had your most recent treatment stop working, and you must have at least one tumor that can be measured on scans.
- You cannot have received any HER2-targeted therapy before.
- Your major organs (like heart, liver, kidneys) must be working well enough, and you must not have other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
This trial tests a new drug called TQB2102 combined with standard chemotherapy (TCbHP) as a first treatment before surgery for HER2-positive early breast cancer. The goal is to see if this combination works better than the current standard therapy.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests an experimental drug called TQB2101 for people with advanced solid tumors that have not responded to standard treatments. The study aims to understand how the body handles the drug and what side effects may occur. It may be an option if your tumor has a specific marker called ROR1.
This study tests a new drug called TQB3126 for people with breast cancer that has worsened after previous treatments. The goal is to see if the drug is safe, how your body processes it, and if it can help shrink or slow the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.